CRISPR Therapeutics (CRSP) to Release Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP) is anticipated to release its earnings data before the market opens on Wednesday, February 19th. Analysts expect CRISPR Therapeutics to post earnings of ($1.20) per share and revenue of $7.29 million for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

CRISPR Therapeutics Trading Up 0.5 %

Shares of NASDAQ CRSP opened at $39.62 on Wednesday. The company has a fifty day moving average price of $42.45 and a 200 day moving average price of $46.40. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The firm has a market cap of $3.38 billion, a PE ratio of -14.00 and a beta of 1.67.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Barclays decreased their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Bank of America cut their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $77.59.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.